Streetbeat News

VNRX

VolitionRx Limited

https://www.volition.com

Industry

Medical - Diagnostics & Research

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Open

0.60

Mkt cap

54M

Volume

389K

High

0.62

P/E Ratio

-1.66

52-wk high

1.23

Low

0.56

Div yield

N/A

52-wk low

0.43

VolitionRx Limited announced that its Nu.Q® Lung Cancer Test successfully differentiated between malignant and benign nodules in a large-scale study, enhancing the diagnostic process for lung cancer patients.

Portfolio Pulse from

December 10, 2024 | 1:15 pm

VolitionRx Limited has announced a registered direct offering, raising up to $1.9 million initially, with potential additional proceeds of $2.7 million from warrant exercises. The offering includes shares sold to insiders and other investors, with warrants exercisable immediately.

Portfolio Pulse from

December 06, 2024 | 2:15 pm

VolitionRx Limited (VNRX) held its Q3 2024 earnings call, discussing company performance and future outlook. Key participants included executives and analysts from various firms.

Portfolio Pulse from

November 15, 2024 | 5:00 pm

VolitionRx Limited has announced its third quarter 2024 financial results and will hold a conference call to discuss these results on November 15, 2024.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

VolitionRx Limited has scheduled its third quarter 2024 earnings conference call and business update for November 15, 2024, at 8:30 a.m. U.S Eastern Time.

Portfolio Pulse from

November 08, 2024 | 1:15 pm

VolitionRx Limited has appointed Timothy I. Still as the new Chairman of its board of directors, effective November 6, 2024.

Portfolio Pulse from

November 06, 2024 | 9:30 pm

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for VolitionRX (AMEX:VNRX) and maintained a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 11:48 am

EF Hutton analyst Tim Moore has assumed coverage of VolitionRX with a Buy rating and set a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 3:08 pm

Benchmark analyst Bruce Jackson has reiterated a Hold rating on VolitionRX (AMEX:VNRX).

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:50 pm

VolitionRX (AMEX:VNRX) reported Q2 EPS of $(0.08), beating the $(0.09) estimate, but missed sales estimates with $395.80K against $480.00K. EPS improved by 42.86% YoY, and sales increased by 82.98% YoY.

Portfolio Pulse from totan@benzinga.com

August 14, 2024 | 8:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.